| abstract |
The invention is directed to a method of treating infections by hepatitis C virus by administering N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.0 2,7 ]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ 6 -benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide and one or more additional antiviral compounds or pharmaceutical compositions containing such compounds. |